Roivant Sciences (NASDAQ:ROIV) Director Sells $1,200,573.48 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 41,861 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total value of $1,200,573.48. Following the transaction, the director directly owned 15,804 shares of the company’s stock, valued at $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $27.70 on Friday. The firm has a market cap of $19.82 billion, a PE ratio of -23.68 and a beta of 1.17. The business’s 50 day simple moving average is $25.92 and its 200 day simple moving average is $21.19. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $30.33.

Analyst Ratings Changes

A number of analysts have recently commented on ROIV shares. Weiss Ratings lowered shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Leerink Partners raised their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Guggenheim lifted their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. HC Wainwright boosted their price target on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG increased its holdings in Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after buying an additional 15,645,836 shares during the last quarter. Morgan Stanley lifted its stake in Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Roivant Sciences by 11,507.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after acquiring an additional 6,877,348 shares during the period. Finally, Norges Bank acquired a new position in shares of Roivant Sciences during the 4th quarter worth about $112,750,000. 64.76% of the stock is owned by institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.